PTCA Drug Coated Balloon (DCB) Catheters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
PTCA Drug Coated Balloon (DCB) Catheters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Summary
GlobalData's Medical Devices sector report, “PTCA Drug Coated Balloon (DCB) Catheters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the PTCA Drug Coated Balloon (DCB) Catheters pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
A Drug Coated Balloon (DCB) Catheter is an anti-restenotic drug coated PTCA balloon catheter intended to prevent re-narrowing of the coronary arteries. DCB Catheters provide fast, short-term, homogenous, local drug delivery. DCB catheters preserve the anatomy of the vessel, promote enhanced vessel healing, and reduce the need for prolonged dual anti-platelet therapy without leaving any metal behind.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the PTCA Drug Coated Balloon (DCB) Catheters under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of PTCA Drug Coated Balloon (DCB) Catheters and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of PTCA Drug Coated Balloon (DCB) Catheters under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
1 About GlobalData
2 Table of Contents
2.1 List of Tables
2.2 List of Figures
3 Introduction
3.1 PTCA Drug Coated Balloon (DCB) Catheters Overview
4 Products under Development
4.1 PTCA Drug Coated Balloon (DCB) Catheters - Pipeline Products by Stage of Development
4.2 PTCA Drug Coated Balloon (DCB) Catheters - Pipeline Products by Territory
4.3 PTCA Drug Coated Balloon (DCB) Catheters - Pipeline Products by Regulatory Path
4.4 PTCA Drug Coated Balloon (DCB) Catheters - Pipeline Products by Estimated Approval Date
7 PTCA Drug Coated Balloon (DCB) Catheters- Recent Developments
7.1 Mar 13, 2024: Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
7.2 Mar 12, 2024: Medtronic To Present At Barclays Global Healthcare Conference
7.3 Mar 10, 2024: Boston Scientific Receives Pre-Market Approval For Agent Paclitaxel Coated-PTCA Balloon Catheter
7.4 Mar 01, 2024: FDA approves Boston Scientific’s drug-coated balloon
7.5 Feb 28, 2024: Boston Scientific Raises $2.2B to Support Purchase of California Medical Device Company
7.6 Feb 23, 2024: Medical Tech Leader, Boston Scientific (BSX), Announces Notes Offering
7.7 Feb 19, 2024: Boston Scientific Appoints Madan Krishnan to Lead India Subcontinent
7.8 Jan 31, 2024: Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
7.9 Jan 16, 2024: Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1
7.1 Jan 05, 2024: Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results
7.11 Oct 26, 2023: Boston Scientific Announces Results for Third Quarter 2023
7.12 Oct 25, 2023: Boston Scientific AGENT Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial
7.13 Oct 04, 2023: Medtronic Names Paolo Di Vincenzo President of the Neuromodulation Business
7.14 Sep 15, 2023: MedAlliance Announces Enrollment of over 1,660 Patients in Landmark SELUTION DeNovo Study
7.15 Sep 06, 2023: MedAlliance Announces Enrollment of First Patient in SELUTION SLR LOVE-DEB Coronary Study
7.16 Aug 26, 2023: Medtronic Q2 2024 Earnings Estimates Increased by William Blair
7.17 Aug 08, 2023: Orchestra Biomed Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue Sirolimus Angioinfusion Balloon in Patients With Coronary In-Stent Restenosis
7.18 Aug 08, 2023: Medtronic to Announce Financial Results for its First Quarter of Fiscal Year 2024
7.19 Jul 19, 2023: Boston Scientific lays off 52 workers as it closes another Silicon Valley facility
7.2 May 30, 2023: Concept Medical’s MagicTouch PTA receives FDA approval to treat SFA
7.21 May 11, 2023: Medtronic to announce financial results for its fourth quarter and full fiscal year 2023
7.22 May 01, 2023: Concept Medical received IDE approval to investigate safety and efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the treatment of small coronary artery disease
7.23 Apr 12, 2023: Medtronic has a layoff in California
8 Appendix
8.1 Methodology
8.2 About GlobalData
8.3 Contact Us
8.4 Disclaimer
2.1 List of Tables
Table 1: PTCA Drug Coated Balloon (DCB) Catheters - Pipeline Products by Stage of Development
Table 2: PTCA Drug Coated Balloon (DCB) Catheters - Pipeline Products by Territory
Table 3: PTCA Drug Coated Balloon (DCB) Catheters - Pipeline Products by Regulatory Path
Table 4: PTCA Drug Coated Balloon (DCB) Catheters - Pipeline Products by Estimated Approval Date
Table 15: ACOART Sirolimus Coated Balloon Catheter - A Prospective, Multicenter, Random Controlled Clinical Trail to Evaluate the Effectiveness and Safety of Sirolimus Coated Balloon Versus a Paclitaxel Coated Balloon in the Treatment of Coronary Bifurcation Lesion
Table 16: ACOART Sirolimus Coated Balloon Catheter - A Prospective, Multicenter, Randomized Controlled Trial Comparing the Efficacy and Safety Between Sirolimus Coated Balloon Catheter and Paclitaxel Coated Balloon Catheter in the Treatment of Femoropopliteal Artery Stenosis
Table 23: SirPlux Duo Drug-Coated Balloon - A Prospective, Single-arm, Multi-center, Feasibility First-in-human Study to Evaluate Safety and Performance of the SirPlux Duo Dual-API Coated PTCA Balloon Catheter to Treat De-novo Lesions in Patients With Symptomatic Stable Coronary Artery Disease
Table 24: B. Braun Interventional Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 25: SeQuent Please - Product Status
Table 26: SeQuent Please - Product Description
Table 27: SeQuent Please ReX Drug Coated PTCA Balloon Catheter - Product Status
Table 28: SeQuent Please ReX Drug Coated PTCA Balloon Catheter - Product Description
Table 29: B. Braun Interventional Systems Inc - Ongoing Clinical Trials Overview
Table 30: SeQuent Please - A Prospective, Multicenter, Clinical Trial to Evaluate the Safety and Effectiveness of the Intracranial Paclitaxel Drug-eluting Balloon Catheters (SeQuent Please CIS) in the Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis and Restenosis after Interventional Therapy
Table 31: SeQuent Please - A Prospective, Randomized, Non-inferiority Trial to Determine the Safety and Efficacy of the BA9 Drug Coated Balloon for the Treatment of In-stent Restenosis: First-in-man Trial: REFORM
Table 32: SeQuent Please - Drug-Coated Balloon in Anticoagulated and Bleeding Risk Patients Undergoing PCI
Table 33: SeQuent Please - Drug-coating Balloon Treatment in Coronary Artery Disease: A Prospective, Multicenter, Registry Study (ULTIMATE-DCB)
Table 34: SeQuent Please - To Evaluate the Long Term Safety and Efficacy of Drug Coated Balloon SeQuent Please in Chinese Coronary Instent Restenosis Patients, a Prospective, Multi-center, Randomization Clinical Trial
Table 35: SeQuent Please ReX Drug Coated PTCA Balloon Catheter - A Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Safety and Efficacy of Paclitaxel Balloon Dilator Versus Paclitaxel Releasing Coronary Balloon Catheter in the Treatment of in Stent Restenosis (ISR)
Table 45: Boston Scientific Corp - Ongoing Clinical Trials Overview
Table 46: Agent Paclitaxel Coated-PTCA Balloon Catheter - AGENT IDE: A Prospective, Randomized (2:1), Multicenter Trial to Assess the Safety and Effectiveness of the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects with In-Stent Restenosis (ISR)
Table 47: Agent Paclitaxel Coated-PTCA Balloon Catheter - Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5
Table 48: Agent Paclitaxel Coated-PTCA Balloon Catheter - Practice Change With Drug-coated Balloon in Patients With multiVessel Coronary Artery Disease
Table 56: Coronary Everolimus Drug-Coated Balloon - Everolimus-Coated Percutaneous Transluminal Coronary Angioplasty Catheter First in Human Clinical Investigation: A Clinical Evaluation in the Treatment of Subjects with In-Stent Restenosis of Previously-treated Coronary Artery Lesions
Table 60: Concept Medical Inc - Ongoing Clinical Trials Overview
Table 61: MagicTouch Sirolimus Coated Balloon Catheter - A Pivotal Study to Support Safety and Efficacy of MagicTouch Sirolimus Coated Balloon for In-stent Restenosis
Table 62: MagicTouch Sirolimus Coated Balloon Catheter - A Study to Evaluate Safety and Effectiveness of the MagicTouch SCB in Small Vessel Coronary Disease Subjects
Table 63: MagicTouch Sirolimus Coated Balloon Catheter - Angiographic Performance Following PCI with A Sirolimus-eluting Balloon in the Treatment of De Novo Coronary Artery Disease: GINGER Study
Table 64: MagicTouch Sirolimus Coated Balloon Catheter - Bifurcation PCI With a Hybrid Strategy with Drug Eluting Balloons Versus a Stepwise Provisional Two-stent Strategy. A Randomized Controlled Trial and Registry
Table 65: MagicTouch Sirolimus Coated Balloon Catheter - Evaluate the Performance of a Sirolimus-Eluting Drug-Coated Balloon (SCB) For the Treatment of Any Coronary Lesions, Including De Novo Lesions and In-Stent Restenosis
Table 66: MagicTouch Sirolimus Coated Balloon Catheter - Magic Touch Sirolimus Coated Balloon (Concept Medical) Versus SeQuent Please Neo Paclitaxel Coated Balloon (Bbraun) for the Treatment of de Novo Coronary Artery Lesions in Small Vessels
Table 67: MagicTouch Sirolimus Coated Balloon Catheter - Paclitaxel- or Sirolimus-Coated Balloons Used For Arteriovenous Fistulas - 2 (Pave-2 Trial): A Double-Blind Randomized Controlled Clinical Trial to Determine the Efficacy of Paclitaxel- or Sirolimus-Coated Balloons in Arteriovenous Fistulas for Haemodialysis
Table 68: MagicTouch Sirolimus Coated Balloon Catheter - Prospective Multi-center Randomized Controlled Trial to Evaluate the Safety and Efficacy of Sirolimus Drug Coated Balloon Versus Non-coated Standard Angioplasty for the Treatment of Infrapopliteal Occlusions in Patients with Peripheral Arterial Disease
Table 69: MagicTouch Sirolimus Coated Balloon Catheter - Sirolimus Drug-coated Balloon Versus Stent Graft for Thrombosed Arteriovenous Graft (SUSTAIN)
Table 70: MagicTouch Sirolimus Coated Balloon Catheter - Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels
Table 71: MagicTouch Sirolimus Coated Balloon Catheter - TicIn for the Treatment of coronAry lesioNs With Drug Eluting Balloons
Table 87: Lepu Medical Technology (Beijing) Co Ltd - Ongoing Clinical Trials Overview
Table 88: Vesselin Drug Coated Coronary Balloon Catheter - Assess the Safety and Efficacy of Lepu Drug Coated Balloon Versus Restore Paclitaxel Eluting Balloon for the Treatment of Coronary Small-vessel Disease: A Prospective, Multicenter, Randomized, Controlled Trial
Table 89: Vesselin Drug Coated Coronary Balloon Catheter - Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions: an Open-label, Multicenter, Randomized, Non-inferiority Trial
Table 99: Prevail DCB Catheter - Drug-Coated Balloon for the Treatment of De Novo and Restenotic Coronary Artery Lesion: a Prospective Observational Study 4
Table 112: Virtue Sirolimus-Eluting Balloon - ISR - Virtue ISR-US Pivotal Study Evaluating the Efficacy and Safety of Virtue SAB for the Treatment of Patients with Coronary In-stent Restenosis (ISR)